Michael J. Labarre sells 10,000 shares of Halozyme Therapeutics, Inc. stock. (NASDAQ:HALO)

VaselineAugust 24, 2024

0 3 minutes read

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Your Free Report) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total value of $617,500.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $10,384,868. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this link.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $61.64 on Friday. The company has a quick ratio of 5.36, a current ratio of 6.64, and a debt-to-equity ratio of 8.44. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $62.58. The company’s fifty day moving average is $54.23 and its 200 day moving average is $45.60. The firm has a market cap of $7.85 billion, a price-to-earnings ratio of 25.47, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO – Get Your Free Report ) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. In the same period last year, the company posted earnings of $0.68 per share. The company’s quarterly revenue was up 4.7% year over year. Equities analysts expect Halozyme Therapeutics, Inc. will record 3.66 EPS for the current fiscal year.

Analysts on Wall Street are forecasting an increase

Want more great investment ideas?

HALO has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th. Goldman Sachs Group boosted their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Benchmark reiterated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Finally, JMP Securities cut their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. . Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Moderate Buy” and an average price target of $59.44, according to MarketBeat.

Get the latest stock analysis on HALO

Institutional investors intervene on halozyme therapy

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its position in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the last quarter. Fifth Third Bancorp boosted its stake in Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 261 shares during the period. First Horizon Advisors Inc. raised its stake in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares during the period. FCF Advisors LLC lifted its position in shares of Halozyme Therapeutics by 1.9% in the first quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 391 shares during the period. Finally, New York State Teachers Retirement System boosted its holdings in shares of Halozyme Therapeutics by 0.4% in the first quarter. New York State Teachers Retirement System now owns 113,820 shares of the biopharmaceutical company’s stock worth $4,630,000 after purchasing an additional 400 shares during the last quarter. 97.79% of shares are held by institutional investors.

About Halozyme Therapeutics

(Get a free report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the delivery of injectable biologics such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.